Replies to post #685516 on NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

Don’t you feel like you’ve been waiting outside a empty house, devoid of all carpets and furniture, with all services and phone lines cut.in the pissing rain .
Desperately hoping the owners will return one day, to let you in ?

[manibiotech]

That’s exactly why I think they have no intention to do it alone , otherwise with what face will they go for uplisting. They are just waiting for approval . And then there is their age .

[skitahoe]

CO, by the time they're qualified to uplist, neither major exchange will care that while on the OTC they failed to have an Annual Meeting in 2023. Frankly at $4 or more they'll represent a company with a market cap of over $5 billion, far bigger than most companies at the time they apply to be on these exchanges. They will be a very different company than they are today.

As for a BP or other partner being necessary to grow, frankly with the right contracts for commercially manufacturing, storing, and distributing their vaccines, it's their contractors who could be doing the lions share of the work. I believe that Advent will be well positioned to do this for all of Europe, and CRL could potentially do it in most, if not all, the remainder of the world. It's up to the company how they want to go about this, but once the EDEN is available in mass the bulk of the business can be in the hands of these contractors. Tracking every disposable cassette from the time it's created until it's recycled will give them an audit trial for every batch of vaccine.

I'm not saying this is how they'll operate, they may grow dramatically and do it themselves. With a dramatically higher stock price and hundreds of millions of authorized shares still available to them, they could raise billions without asking shareholders to authorize more shares, so such explosive building growth is possible. Personally I believe they want to develop a huge market cap without becoming a huge company, with the EDEN approved and good contracts, they could do this with limited corporate growth.

I'm just suggesting that they have many choices. With approval, I believe they'll initiate both trials with DCVax-Direct to work it toward tumor agnostic approval, and on new trials for DCVax-L leading to a label change that's tumor agnostic. If they manage these trials, and allow contractors to handle the commercial manufacturing, storage, distribution and sales of DCVax-L they'll be well positioned for explosive growth. Of course they'll also be working for approval from all authorities, first the other three in the trial, but then expansion throughout the globe. Again, they'll use contractors in creating the changes needed to what's been created in approaching the UK.

Gary